Jubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore and net debt at Rs. 2,457 crore. In FY24, the company reported revenue of Rs. 6,772 crore and a net profit of Rs. 195 crore. The net debt to Ebitda ratio improved from 2.93x to 2.48x.
